All
National Eye Institute grants funding to WVU to study the mechanism of retinal degeneration
January 19th 2022According to researchers, gaining a good understanding of what Musashi proteins do and how to manipulate their function could lead to the development of a universal therapy for blinding diseases.
REGENXBIO announces second pivotal trial, ASCENT, in RGX-314 clinical program
January 18th 2022ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.
Pupillary sizes differ in active and resolved COVID-19 cases, study finds
January 18th 2022The investigators believe that, based on their findings, the impact of COVID-19 on the autonomous nervous system warrants further prospective studies and assessment of pupillary function might be a useful test for determining autonomic dysfunction.
2022 is "Year of Children's Vision," as declared by Prevent Blindness
December 22nd 2021According to the organization, the goal is to highlight and address the diverse and critical vision and eye health needs of children and to improve outcomes through advocacy, public health, education, and awareness.